Anti-EGFR Antibody

Price:
Size:
Number:

Anti-EGFR Antibody (Rabbit Polyclonal antibody) General Information

Product name
Anti-EGFR Antibody
Validated applications
ELISA
Species reactivity
Reacts with: Rhesus
Specificity
Rhesus EGFR
Immunogen
Recombinant Rhesus EGFR / HER1 / ErbB1 Protein (Catalog#90317-K08H)
Preparation
Produced in rabbits immunized with purified, recombinant Rhesus EGFR / HER1 / ErbB1 (Catalog#90317-K08H; XP_001107305.1; Met1-Ser645). Total IgG was purified by Protein A affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-EGFR Antibody (Rabbit Polyclonal antibody) Validated Applications

Application Dilution
ELISA 1:1000-1:2000
Please Note: Optimal concentrations/dilutions should be determined by the end user.

EGFR Background Information

As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently.
Full Name
epidermal growth factor receptor
References
  • Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2): 211-25.
  • Giaccone, G. (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann. Oncol. 16(4): 538-48.
  • Yarden, Y., et al. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2(2): 127-37.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait